Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rapport Therapeutics, Inc. ( (RAPP) ) has shared an update.
On April 21, 2026, Rapport Therapeutics reported follow-up data from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, showing sustained and in some cases improved seizure control after dosing stopped. In weeks 9–12, patients recorded median reductions of 80% in long episodes and 90% in clinical seizures versus baseline, with clinically meaningful reductions persisting through weeks 13–16 alongside a favorable tolerability profile.
Pharmacokinetic analyses indicated RAP-219 has an approximately 22-day half-life, with plasma levels remaining in the targeted therapeutic range and supporting continued receptor occupancy over the eight-week follow-up. These results, presented at the 2026 American Academy of Neurology meeting, strengthen Rapport’s case for RAP-219 as a differentiated therapy and support the company’s move toward pivotal Phase 3 trials in focal onset seizures and broader development across additional seizure types and bipolar mania.
The most recent analyst rating on (RAPP) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
The score is held back primarily by pre-revenue fundamentals with widening losses and substantial cash burn, despite a strong, low-leverage balance sheet. Technicals are supportive with a clear uptrend and positive momentum, but overbought readings raise near-term risk. Valuation remains weak given the negative P/E and no dividend support.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small-molecule precision medicines for neurological and psychiatric disorders. Its lead candidate, RAP-219, is a TARPγ8-specific AMPA receptor negative allosteric modulator designed to provide a differentiated safety and efficacy profile in seizure disorders by targeting brain regions where focal seizures originate while sparing areas associated with common adverse events.
The company is advancing RAP-219 across multiple seizure indications and bipolar mania, and is also developing a long-acting injectable formulation to extend therapeutic coverage. Rapport positions itself in the competitive epilepsy and CNS market as a potential provider of best-in-class, targeted therapies for drug-resistant patients, supported by ongoing and planned Phase 2 and Phase 3 clinical programs.
Average Trading Volume: 323,231
Technical Sentiment Signal: Buy
Current Market Cap: $1.75B
See more insights into RAPP stock on TipRanks’ Stock Analysis page.